BIOBADASER Registry data on comparative drug-dependent cancer risk in patients with prior cancer. 352 patients. 32 incident cancers (14 NMSC). No difference between agents, but wide CIs @RheumNow #EULAR2022 OP0138 https://t.co/NEZSL2AQhC https://t.co/EG0NflXXW6

• EULAR Abstract Archive

Unizony et al. Case series of tocilizumab + 8 weeks steroid in GCA. 30 patients, 50% new 50% relapsing. 77% in sustained remission at week 52! No vision loss. Exciting, needs an RCT @RheumNow #EULAR2022 OP0185 https://t.co/ohBYIWYxBC https://t.co/fsn4x17Hwv

• EULAR Abstract Archive

#Behcets. If topical oracort / steroids don’t work for Mucosal ulcers consider topical #tacrolimus https://t.co/7ZiLfdwZoP

• Aurelie Najm on Twitter: "Behcet disease: 
RCT Topical Tacrolimus for …

New #SLE drug to pay attention to! iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and reduce IFN sig while enhancing regulatory T cells- Prof T Dorner #EULAR2022 @rheumnow https://t.co/q39pxK3gFJ

Spanish safety registry BIOBADASER 3.0: *9000+ pts with IMID treated w/ bio or tsDMARDS *352 pts w/ prior malignancy *32 incident malignancies -> 27 events/1000PY NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups @RheumNow #EULAR2022 OP0138 https://t.co/8IyC6NdGCF

The PROOF study showed the predictors of radiographic progression included male gender HR 3.16, good response to NSAIDs HR 4.66, fulfillment of the imaging arm HR 6.64 and HLA-B27+ HR 3.99 by Poddubnyy et al #EULAR2022 @RheumNow OP0149

#EULAR2022 OP0139 Has your pt asked about sexual fxn? Sexual dysfxn (SD) (CSFQ-14 questionnaire) and joint disease 188 AI pts, 89 controls Nearly 50% of RA pts had SD, 30% in PsA. Only 6% in control group! High depression in group, but not found as rf @RheumNow https://t.co/WvBw3cnFKC

#ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refractory #lupus, antiCD38i, drugs i. RCTs=hope for pts. #EULAR2022 T Dorner @RheumNow @eular_org https://t.co/2BReU5bhG0

Tang et al. Prediction of 6-month mortality in MDA5-DM. Fever, ferritin≥1250, and positive carcinoembryonic antigen (CEA) predictive in Chinese population @RheumNow #EULAR2022 OP0163 https://t.co/byDiHZhcGK https://t.co/95Wx4quQMP

• EULAR Abstract Archive

No need to switch TNFi during pregnancy. Study compared high placental vs. low placental transfer TNFi- no sig difference for SIE in childhood. Dr. L Flatman comparing different TNFi in pregnancy: 26,000 offsprings #EULAR2022 @rheumnow OP0130 https://t.co/IF5hepQoHc

#SLE hospitalized pts had worse outcomes than matched controls ? Due to interfonopathy and poor handling of viral infections - worse if #Rituximab or #MMF T Dormer BUT vaccination works if enough B cells responding to #Covid vaccine #EULAR2022 #Lupus scientific session @RheumNow https://t.co/MBb3Dvxmqp

The GESPIC cohort reports in Axial PsA, 75% had inflammatory back pain, 45% met NY criteria for AS, 55% with active inflammatory change in SI joint and 60% in the spine. This is where the overlap between Axial PsA and Axial SpA happens, Kading et al #EULAR2022 @RheumNow OP0026

Pregnancy outcomes in SpA Increased risk of ❗️gestational diabetes aRR 1.88 ❗️Cesarean delivery aRR 1.54 & 1.23 ❗️preterm birth aRR 1.52 ❗️trend for increased infection in 1st year of life in newborns aRR 1.23. #EULAR2022 @RheumNow OP0126 https://t.co/jMryB5UXQr

Million $$$ questions presented to Prof T Dorner: anifrolumab vs. belimumab for #SLE? He prefers belimumab d/t more data on multiple organ manifestations ^ it might be protective in pts w/ COVID19 infection. If skin dz is predominant, then anifrolumab #EULAR2022 @rheumnow

Patient with 12 weeks inflamm-sounding arthralgias and functional impairment, high titre RF/CCP, osteitis on MRI, no clinical synovitis on exam. Do you suggest to patient to treat with methotrexate? #EULAR2022 @RheumNow